Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer

Adding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone.
MDedge News

source https://www.medscape.com/s/viewarticle/997600?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?